Transverse leukonychia (Leukonychia striata or Muehrcke’s lines) has been described with the use of several drugs in oncology, mainly chemotherapeutic agents. This condition is thought to represent an abnormality of the vascular nail bed. As the diagnosis is clinical and the condition is self-limited, referral to other specialists is usually not required. We report the first case of transverse leukonychia related to the use of transretinoic acid for acute promyelocytic leukemia. Physician awareness of transverse leukonychia is important in order to reassure the patients and avoid unnecessary (and often not inexpensive) diagnostic work-up.
VassalloCBrazzelliVArdigòM. The irreplaceable image: nails changes in onco-hematologic patients. Haematologica2001; 86(3): 334–336.
2.
UnamunoPFernandez-LopezESantosC. Leukonychia due to cytostatic agents. Clin Exp Dermatol1992; 17(4): 273–274.
3.
Modesto dos SantosVSugaiTACezarBF. Transverse leukonychia: a case report. West Afr J Med2005; 24(2): 181–182.
4.
GulUKilicA. Muehrcke’s lines on nails after cyclophosphamide/adriamycin/fluorouracil. Ann Pharmacother2004; 38(6): 1089–1090.
5.
BoreckyDJStephensonJJKeelingJH. Idarubicin-induced pigmentary changes of the nails. Cutis1997; 59(4): 203–204.
6.
AbramsCKSiramSMGalsimC. Selenium deficiency in long-term total parenteral nutrition. Nutr Clin Pract1992; 7: 175–178.
7.
IpekYHulyaDMelihA. Disseminated exfoliative dermatitis associated with all-transretinoic acid in the treatment of acute promyelocytic leukemia. Case Report Med2012; 2012: 236174–236174.
8.
OnderMOztaşMOOztaşP. Isotretinoin-induced nail fragility and onycholysis. J Dermatolog Treat2001; 12(2): 115–116.
